-
Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022
-
View Affiliations Hide AffiliationsNicole Berens-Rihanberens itg.be
-
View Collaborators
ITM Monkeypox Study Group: Christophe Van Dijck, Irith De Baetselier, Dorien Van den Bossche, Eric Florence, Wim Adriaensen, Jasmine Coppens, Fien Vanroye, Kadrie Ramadan, Karin Van Looveren, Jolien Baeyens, Leo Heyndrickx, Hanne Rasson, Jacob Verschueren, Stefanie Bracke, Leen Vandenhove, Jef Vanhamel, Bea VuylstekeView Citation Hide Citation
Citation style for this article: . Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022. Euro Surveill. 2022;27(48):pii=2200894. https://doi.org/10.2807/1560-7917.ES.2022.27.48.2200894 Received: 21 Nov 2022; Accepted: 01 Dec 2022
Abstract
Vaccination is important in containing the 2022 mpox (formerly monkeypox) epidemic. We describe five Belgian patients with localised severe symptoms of proctitis and penile oedema, occurring between 4 and 35 days after post-exposure preventive vaccination or after one- or two-dose off-label pre-exposure preventive vaccination with MVA-BN vaccine. Genome sequencing did not reveal evidence for immune escape variants. Healthcare workers and those at risk should be aware of possible infections occurring shortly after vaccination and the need for other preventive measures.
Full text loading...